Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic, Inc. (NASDAQ: HOLX) has successfully completed its acquisition of Biotheranostics, a leader in molecular oncology, for approximately $230 million. Biotheranostics specializes in molecular diagnostic tests such as the Breast Cancer Index and CancerTYPE ID, which aid in predicting treatment benefits and optimizing therapy for patients with uncertain cancers. Following the acquisition, Hologic aims to grow in the expanding oncology market, leveraging the National Comprehensive Cancer Network's recent endorsement of Breast Cancer Index as a key predictive tool for hormone-receptor positive breast cancer.
A recent study published in the Journal of the American College of Radiology highlights significant racial disparities in breast cancer screening, particularly in digital breast tomosynthesis (DBT). The research, commissioned by Hologic (HOLX), analyzed data from over 385,000 women across various racial backgrounds and found that Black women were less likely to receive DBT mammograms, despite their higher mortality rate from breast cancer. Hologic is dedicated to addressing these disparities through partnerships and initiatives aimed at increasing access to advanced screening technologies for Black women.
AMETEK announced the appointment of Karleen Oberton to its Board of Directors, effective February 11, 2021. Oberton currently serves as CFO of Hologic and has over 30 years of experience in public accounting, biotechnology, and medical device manufacturing. Her expertise in finance and executive leadership is expected to enhance AMETEK's board dynamics. The company reported 2020 sales exceeding $4.5 billion and aims for double-digit growth in earnings per share over the business cycle.
Hologic, Inc. (Nasdaq: HOLX) will present at several upcoming virtual investor conferences, highlighting its commitment to women's health technology. Key events include:
- BTIG Virtual MedTech Conference on February 17 at 10:30 a.m. ET
- Citi’s Healthcare Services Conference on February 24 at 11:40 a.m. ET
- SVB Leerink’s Global Healthcare Conference on February 25 at 1:00 p.m. ET
- Raymond James Institutional Investors Conference on March 1 at 1:20 p.m. ET
All presentations will be webcast live and accessible on Hologic's investor website.
Hologic, Inc. (HOLX) has entered into a multi-year strategic collaboration with Google Cloud to integrate machine learning technologies with its Genius™ Digital Diagnostics System. This partnership aims to enhance cervical cancer screening by using AI for improved identification of pre-cancerous lesions and cancer cells. Hologic's President emphasized this as a natural progression in their 30-year commitment to cervical cancer screening. While the Genius system is CE-marked for the European market, it is not yet available in the U.S. Financial terms of the collaboration were not disclosed.
Hologic reported an impressive financial performance for the fiscal Q1 ended December 26, 2020, with revenues soaring by 89.3% to $1.61 billion. The growth was driven by a 457.6% surge in molecular diagnostics revenue, fueled by demand for SARS-CoV-2 tests. The company also announced acquisitions of Biotheranostics and SOMATEX, with cash flow from operations at $650 million. Although net income rose to $654.4 million, net margins declined by 480 bps. Hologic expects continued strong performance for Q2 with guidance of $1.50 - $1.56 billion in revenue.
Hologic, Inc. (Nasdaq: HOLX) will announce its financial results for Q1 of fiscal 2021 on January 27, after market close. A conference call is set for 4:30 p.m. ET, accessible at 888-204-4368 (U.S.) or +1 323-994-2093 (international). Participants are encouraged to join 5-10 minutes early. The call will also be available via webcast on Hologic's investor website and archived for 30 days.
Hologic is dedicated to advancing women's health through innovative medical technologies.
Hologic, Inc. (Nasdaq: HOLX) announced preliminary revenue results for Q1 fiscal 2021, expecting revenues of approximately $1,609.8 million, up 89.3% year-over-year. This exceeds prior guidance of $1,350-$1,425 million. Diagnostics revenue surged 262.2% to $1,128.2 million, fueled by nearly 30 million COVID-19 tests. The company will report full results on January 27, 2021, and announced a $1 billion share repurchase plan while paying off $250 million of debt.
Hologic, Inc. (Nasdaq: HOLX) has announced its acquisition of Biotheranostics, Inc. for approximately $230 million. This strategic move aims to enhance Hologic's position in the oncology sector, particularly in women's health diagnostics. Biotheranostics offers advanced molecular diagnostic tests for breast and metastatic cancers, which align with Hologic's broader goals. The acquisition is projected to be dilutive to Hologic's non-GAAP earnings in 2021 but expected to break-even in 2022 and become accretive thereafter. The transaction is anticipated to close in February 2021, pending regulatory approvals.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
What does Hologic Inc. specialize in?
Where is Hologic Inc. headquartered?
What are the main segments of Hologic’s business?
Which segment contributes the most to Hologic's revenue?
How has the pandemic affected Hologic’s business segments?
What percentage of Hologic’s revenue comes from the United States?
How did the acquisition of Gen-Probe impact Hologic?
How can I stay updated with Hologic's latest news?
What is Hologic’s approach to healthcare?
What percentage of Hologic’s revenue comes from international markets?
